Global artificial organs market is acclaimed to be one of the most profitable verticals within the healthcare and medical devices space and is projected to grow substantially by 2026. The market expansion can be associated with factors such as increasing occurrence of organ failures, especially among the elderly population, and lack of organ donors in many parts of the world.

Artificial organs are basically human made tissues or organs that are implanted or integrated into the human body and interfaced with living tissues to replace a natural organ, to duplicate or improve specific functionality. Research and development in the field is expected to gather pace over the next few years and biotechnology firms are likely to lead innovation in the development of artificial organs.

Depending upon the type of organ, artificial organs industry is segmented into artificial lungs, artificial heart, artificial liver, artificial kidney, and artificial pancreas, among others. Global artificial pancreas market size is estimated to record a robust CAGR of over 9.5% through 2026. The product demand will be mainly propelled by high incidence of diabetes worldwide and ongoing efforts in new product development.

In patients suffering from diabetes or other gastrointestinal diseases, artificial pancreas can help transfer insulin across membranes in response to fatty acids and glucose. It is used to replicate endocrine functionality of healthy pancreas for those patients who need it. The artificial organ can also be used to enhance insulin replacement therapy and ease the burden of the therapy for insulin dependent patients.

On the basis of material type, artificial organs industry is classified into silicon, steel, plastic, and others. Silicon materials are likely to capture a market share of more than 35% in terms of revenue by the year 2026. Biotechnology companies and researchers are currently focusing on development of more durable artificial organs using innovative materials.

The use of silicon nano-porous membranes coated with polyethylene glycol (PEG) and formed on a silicon support structure can help replicate majority of the properties and functionality of healthy natural organs. Numerous research organizations are exploring ways to utilize silicon nano-porous membranes for development of artificial kidneys and protection of transplanted pancreas tissues from immune destruction.

In terms of the regional landscape, Asia Pacific artificial organs industry size is slated to witness a healthy CAGR of more than 9.5% through 2026, with an increased occurrence of organ failures and the lack of organ donors. The region has experienced a massive upsurge in incidence of orthopedic diseases, particularly among the geriatric population base as older people are more susceptible to the risk of numerous health problems. These trends are likely to fuel the adoption of advanced healthcare products and devices.